Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors

Autor: Lisa DeTora, Krupa D, Bolognese J, Rs, Sperling, Ew, Ehrich

Publikováno v: Scopus-Elsevier
Europe PubMed Central

To evaluate the efficacy of rofecoxib (Vioxx) in subpopulations of patients with osteoarthritis (OA) identified by demographic or baseline disease characteristics, or varied OA involvement.Data were combined from three 6-week double blind trials in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1c6a28e06edb8a18fcf3c38f65f7a02a
https://pubmed.ncbi.nlm.nih.gov/11708424

Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.

Autor: Martin WF; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll)., Correll CU; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll)., Weiden PJ; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll)., Jiang Y; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll)., Pathak S; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll)., DiPetrillo L; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll)., Silverman BL; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll)., Ehrich EW; Alkermes, Inc., Waltham, Mass. (Martin, Weiden, Jiang, Pathak, DiPetrillo, Silverman, Ehrich); and Hofstra Northwell School of Medicine, Hempstead, N.Y., and Zucker Hillside Hospital, Psychiatry, Glen Oaks, N.Y. (Correll).

Publikováno v: The American journal of psychiatry [Am J Psychiatry] 2019 Jun 01; Vol. 176 (6), pp. 457-467. Date of Electronic Publication: 2019 Mar 08.

Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.

Autor: Nasrallah HA; Department of Neurology and Psychiatry, Saint Louis University School of Medicine, 1438 S. Grand Blvd, St Louis, MO 63104. hnasral@slu.edu.; Saint Louis University School of Medicine, St Louis, Missouri, USA., Newcomer JW; Florida Atlantic University, Charles E. Schmidt College of Medicine, Boca Raton, Florida, USA., Risinger R; Alkermes, Inc, Waltham, Massachusetts, USA., Du Y; Alkermes, Inc, Waltham, Massachusetts, USA., Zummo J; Alkermes, Inc, Waltham, Massachusetts, USA., Bose A; Alkermes, Inc, Waltham, Massachusetts, USA., Stankovic S; Alkermes, Inc, Waltham, Massachusetts, USA., Silverman BL; Alkermes, Inc, Waltham, Massachusetts, USA., Ehrich EW; Alkermes, Inc, Waltham, Massachusetts, USA.

Publikováno v: The Journal of clinical psychiatry [J Clin Psychiatry] 2016 Nov; Vol. 77 (11), pp. 1519-1525.

A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.

Autor: Meltzer HY; Department of Psychiatry and Physiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois., Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW

Publikováno v: The Journal of clinical psychiatry [J Clin Psychiatry] 2015 Aug; Vol. 76 (8), pp. 1085-90.

A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder.

Autor: McElroy SL; Lindner Center of HOPE, Research Institute, Mason, OH 45040, USA. susan.mcelroy@lindnercenter.org, Guerdjikova AI, Blom TJ, Crow SJ, Memisoglu A, Silverman BL, Ehrich EW

Publikováno v: The International journal of eating disorders [Int J Eat Disord] 2013 Apr; Vol. 46 (3), pp. 239-45. Date of Electronic Publication: 2013 Feb 05.